| Year |
Citation |
Score |
| 2020 |
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, ... ... Miller TP, et al. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000999. PMID 32658627 DOI: 10.1200/Jco.20.00999 |
0.422 |
|
| 2016 |
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, et al. Phase 1 study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed or refractory chronic lymphocytic leukemia. Haematologica. PMID 27151992 DOI: 10.3324/Haematol.2015.140806 |
0.354 |
|
| 2016 |
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leukemia & Lymphoma. 1-11. PMID 26758422 DOI: 10.3109/10428194.2015.1135431 |
0.463 |
|
| 2015 |
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 125: 236-41. PMID 25395425 DOI: 10.1182/Blood-2014-06-584623 |
0.432 |
|
| 2014 |
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, et al. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 124: 1259-65. PMID 25016003 DOI: 10.1182/Blood-2014-04-570044 |
0.432 |
|
| 2014 |
Mahadevan D, Morales C, Cooke LS, Manziello A, Mount DW, Persky DO, Fisher RI, Miller TP, Qi W. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2. Plos One. 9: e95184. PMID 24893165 DOI: 10.1371/Journal.Pone.0095184 |
0.365 |
|
| 2014 |
Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. British Journal of Haematology. 166: 382-9. PMID 24749780 DOI: 10.1111/Bjh.12906 |
0.502 |
|
| 2014 |
Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, et al. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. American Journal of Hematology. 89: 639-45. PMID 24633940 DOI: 10.1002/Ajh.23709 |
0.333 |
|
| 2014 |
Barr PM, Li H, Spier CM, Mahadevan D, Friedberg JW, LeBlanc ML, Ul Haq M, Flowers C, Wagner-Johnston ND, Cheson BD, Horwitz SM, Miller TP, Fisher RI. U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). Journal of Clinical Oncology. 32: 8523-8523. DOI: 10.1200/Jco.2014.32.15_Suppl.8523 |
0.383 |
|
| 2014 |
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada SD, Stea BD, Press OW, Constine L, Barton K, LeBlanc M, Smith S, Fisher RI, Friedberg JW. Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma Blood. 124: 4414-4414. DOI: 10.1182/Blood.V124.21.4414.4414 |
0.478 |
|
| 2013 |
Rogowitz E, Babiker HM, Krishnadasan R, Jokerst C, Miller TP, Bookman M. Heart of lymphoma: primary mediastinal large B-cell lymphoma with endomyocardial involvement. Case Reports in Oncological Medicine. 2013: 814291. PMID 24194994 DOI: 10.1155/2013/814291 |
0.361 |
|
| 2013 |
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. The New England Journal of Medicine. 369: 1681-90. PMID 24171516 DOI: 10.1056/Nejmoa1301077 |
0.384 |
|
| 2013 |
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6624-32. PMID 24130072 DOI: 10.1158/1078-0432.Ccr-13-1120 |
0.435 |
|
| 2013 |
Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1587-93. PMID 23504948 DOI: 10.1093/Annonc/Mdt070 |
0.384 |
|
| 2013 |
Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 121: 3547-53. PMID 23386127 DOI: 10.1182/Blood-2012-09-454694 |
0.315 |
|
| 2013 |
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 314-20. PMID 23233710 DOI: 10.1200/Jco.2012.42.4101 |
0.476 |
|
| 2013 |
Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leukemia Research. 37: 434-9. PMID 23153524 DOI: 10.1016/J.Leukres.2012.10.017 |
0.407 |
|
| 2013 |
Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 441-8. PMID 23041589 DOI: 10.1093/Annonc/Mds429 |
0.377 |
|
| 2013 |
Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer. 119: 371-9. PMID 22833464 DOI: 10.1002/Cncr.27733 |
0.479 |
|
| 2013 |
Badari AR, Zaid MA, Unger JM, Rimsza LM, Marron M, Fisher RI, Miller TP, Stopeck A. Markers of angiogenesis and hypoxia to cell of origin (COO) subtypes of DLBCL: Correlative studies from S0515, a phase II trial of R-CHOP plus bevacizumab. Journal of Clinical Oncology. 31: 8562-8562. DOI: 10.1200/Jco.2013.31.15_Suppl.8562 |
0.327 |
|
| 2013 |
Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Miller TP, Gerecitano JF, Kipps TJ, Anderson MA, Huang DCS, Darden DE, Gressick LA, Nolan CE, Yang J, Busman TA, et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 31: 7018-7018. DOI: 10.1200/Jco.2013.31.15_Suppl.7018 |
0.347 |
|
| 2013 |
Barr PM, Briehl MM, Bernstein SH, Friedberg JW, Baran A, Peterson DR, Persky DO, Casulo C, Herr MM, Littleton J, Cebula E, Schwartz M, Puvvada SD, Dorr RT, Fisher RI, ... Miller TP, et al. Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study Blood. 122: 89-89. DOI: 10.1182/Blood.V122.21.89.89 |
0.485 |
|
| 2013 |
Davids MS, Pagel JM, Kahl BS, Wierda WG, Miller TP, Gerecitano JF, Kipps TJ, Anderson M, Huang DCS, Rudersdorf NK, Gressick LA, Montalvo NP, Ccrp, Yang J, Busman TA, et al. Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Blood. 122: 872-872. DOI: 10.1182/Blood.V122.21.872.872 |
0.351 |
|
| 2013 |
Puvvada SD, Persky DO, Inclan L, Schatz JH, Chase EM, Guillen J, Roe D, Miller TP. Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study Blood. 122: 4404-4404. DOI: 10.1182/Blood.V122.21.4404.4404 |
0.47 |
|
| 2013 |
Persky DO, Mahadevan D, Miller TP, Puvvada SD, McDonagh K, Hayslip J, Park SI, Ruan J, Rosen PJ, Iyer SP, Stefanovic A, Zhang B, Zhou X, Ullmann CD, Leonard EJ, et al. Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas Blood. 122: 3027-3027. DOI: 10.1182/Blood.V122.21.3027.3027 |
0.371 |
|
| 2013 |
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Barnett E, Marine J, et al. Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Blood. 122: 1630-1630. DOI: 10.1182/Blood.V122.21.1630.1630 |
0.365 |
|
| 2012 |
Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, Cerhan JR, Zelenetz AD, Hirata J, Miller TP. Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National Lymphocare Study Journal of Clinical Oncology. 30: 3368-3375. PMID 22915662 DOI: 10.1200/Jco.2011.40.6546 |
0.427 |
|
| 2012 |
Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 120: 1210-7. PMID 22734071 DOI: 10.1182/Blood-2012-04-423079 |
0.484 |
|
| 2012 |
Nabhan C, Byrtek M, Taylor MD, Friedberg JW, Cerhan JR, Hainsworth JD, Miller TP, Hirata J, Link BK, Flowers CR. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study Cancer. 118: 4842-4850. PMID 22434428 DOI: 10.1002/Cncr.27513 |
0.396 |
|
| 2012 |
Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2210-9. PMID 22374334 DOI: 10.1158/1078-0432.Ccr-11-2413 |
0.405 |
|
| 2012 |
Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica. 97: 937-42. PMID 22271896 DOI: 10.3324/Haematol.2011.050419 |
0.357 |
|
| 2012 |
Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, Mahadevan D. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. International Journal of Cancer. Journal International Du Cancer. 130: 2997-3005. PMID 21796626 DOI: 10.1002/Ijc.26324 |
0.388 |
|
| 2012 |
Persky DO, Bernstein SH, Goldman BH, Rimsza LM, Fisher RI, Miller TP. A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E18536 |
0.423 |
|
| 2012 |
Adab K, Persky DO, Guillen-Rodriguez J, Rimsza LM, Frutiger YM, Haidau A, Telfer MC, Braik T, Catchatourian R, Miller TP. Geographic variation of extranodal sites of mucosal associated lymphoid tissue lymphoma (MALToma): Analysis of series from two institutions. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E18534 |
0.342 |
|
| 2012 |
Press OW, Unger JM, LeBlanc ML, Rimsza LM, Friedberg JW, Czuczman MS, Kaminski MS, Braziel RM, Spier CM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. Journal of Clinical Oncology. 30: 8001-8001. DOI: 10.1200/Jco.2012.30.15_Suppl.8001 |
0.456 |
|
| 2012 |
Seymour JF, Davids MS, Anderson MA, Kipps TJ, Wierda WG, Pagel JM, Kahl BS, Miller TP, Darden DE, Nolan CE, Gressick LA, Xiong H, Huang DCS, Chyla BJ, Busman TA, et al. The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study Blood. 120: 3923-3923. DOI: 10.1182/Blood.V120.21.3923.3923 |
0.391 |
|
| 2012 |
Mahadevan D, Qi W, Liu X, Cooke LS, Agarwal A, Persky DO, Miller TP. Abstract 3684: Targeting Aurora kinase in peripheral T-cell non-Hodgkin's lymphomas Cancer Research. 72: 3684-3684. DOI: 10.1158/1538-7445.Am2012-3684 |
0.444 |
|
| 2011 |
Nooka AK, DeJoubner NJ, Nabhan C, Zhou X, Taylor M, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Levy D, Hirata J, Flowers C. Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8036. PMID 28023579 DOI: 10.1200/Jco.2011.29.15_Suppl.8036 |
0.368 |
|
| 2011 |
Link BK, Miller TP, Byrtek M, Cerhan JR, Zelenetz AD, Dillon H, Flowers C, Friedberg JW. Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8049. PMID 28023565 DOI: 10.1200/Jco.2011.29.15_Suppl.8049 |
0.34 |
|
| 2011 |
Rimsza LM, Wright G, Schwartz M, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Cook JR, Tubbs RR, Braziel RM, Delabie J, Miller TP, Staudt LM. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues Clinical Cancer Research. 17: 3727-3732. PMID 21364035 DOI: 10.1158/1078-0432.Ccr-10-2573 |
0.377 |
|
| 2011 |
Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, Persky DO, Miller TP, Mahadevan D. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochemical Pharmacology. 81: 881-90. PMID 21291867 DOI: 10.1016/J.Bcp.2011.01.017 |
0.428 |
|
| 2011 |
Press OW, Unger JM, Rimsza LM, Friedberg J, LeBlanc M, Czuczman MS, Kaminski MS, Braziel RM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma Blood. 118: 98-98. DOI: 10.1182/Blood.V118.21.98.98 |
0.44 |
|
| 2011 |
Mahadevan D, Cooke L, Stejskal A, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W. Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma Blood. 118: 2721-2721. DOI: 10.1182/Blood.V118.21.2721.2721 |
0.404 |
|
| 2011 |
Mahadevan D, Cooke LS, Stejskal A, Persky DO, Miller TP, Qi W. Abstract LB-225: MLN8237 (aurora A inhibitor) plus vincristine plus rituximab is curative in mice bearing aggressive B-cell non-Hodgkin's lymphoma Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-225 |
0.349 |
|
| 2010 |
Stopeck AT, Unger JM, Rimsza LM, Farnsworth B, LeBlanc M, Iannone M, Fisher RI, Miller TP. Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515 Blood. 116: 591-591. DOI: 10.1182/Blood.V116.21.591.591 |
0.46 |
|
| 2010 |
Friedberg JW, Unger JM, Burack WR, Gopal AK, LeBlanc M, Press OW, Miller TP, Fisher RI. R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Blood. 116: 590-590. DOI: 10.1182/Blood.V116.21.590.590 |
0.432 |
|
| 2010 |
Mahadevan D, Cooke L, Liu X, Persky DO, Spier CM, Miller TP, Qi W. Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin's Lymphoma Blood. 116: 3933-3933. DOI: 10.1182/Blood.V116.21.3933.3933 |
0.401 |
|
| 2010 |
Mahadevan D, Liu X, Persky DO, Miller TP, Squires MS, Qi W. AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma Blood. 116: 3930-3930. DOI: 10.1182/Blood.V116.21.3930.3930 |
0.389 |
|
| 2010 |
Tardif HL, Yao S, Goldman BH, Spier CM, LeBlanc ML, Rimsza LM, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM. Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas Blood. 116: 321-321. DOI: 10.1182/Blood.V116.21.321.321 |
0.349 |
|
| 2010 |
Flowers CR, Taylor M, Byrtek M, Hirata JH, Cerhan J, Hainsworth J, Link B, Miller TP, Dillon H, Friedberg JW. Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS) Blood. 116: 1768-1768. DOI: 10.1182/Blood.V116.21.1768.1768 |
0.359 |
|
| 2009 |
Persky DO, Miller TP. Localized large cell lymphoma: is there any need for radiation therapy? Current Opinion in Oncology. 21: 401-6. PMID 19593138 DOI: 10.1097/Cco.0B013E32832F3C8B |
0.403 |
|
| 2009 |
Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leukemia & Lymphoma. 50: 728-35. PMID 19373598 DOI: 10.1080/10428190902856808 |
0.457 |
|
| 2009 |
Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 114-9. PMID 19047289 DOI: 10.1200/Jco.2008.16.8021 |
0.416 |
|
| 2009 |
Rimsza LM, Wright G, Schwartz M, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Cook JR, Tubbs RR, Braziel RM, Delabie J, Miller TP, Fisher RI, et al. Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project. Blood. 114: 620-620. DOI: 10.1182/Blood.V114.22.620.620 |
0.353 |
|
| 2009 |
Mahadevan D, Qi W, Cooke L, Lui X, Persky DO, Rimsza LM, Miller TP. Targeting Aurora Kinase in Aggressive B-Cell Non-Hodgkin's Lymphomas. Blood. 114: 284-284. DOI: 10.1182/Blood.V114.22.284.284 |
0.41 |
|
| 2009 |
Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, LeBlanc M, Maloney DG, Miller TP, Press OW, Rimsza LM. Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone. Blood. 114: 111-111. DOI: 10.1182/Blood.V114.22.111.111 |
0.4 |
|
| 2008 |
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, ... ... Miller TP, et al. Stromal gene signatures in large-B-cell lymphomas. The New England Journal of Medicine. 359: 2313-23. PMID 19038878 DOI: 10.1056/Nejmoa0802885 |
0.443 |
|
| 2008 |
Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, Kasamon Y, Miller TP, Fisher RI. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 86: 215-22. PMID 18645482 DOI: 10.1097/Tp.0B013E3181761659 |
0.338 |
|
| 2008 |
Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 112: 3425-33. PMID 18544678 DOI: 10.1182/Blood-2008-02-137372 |
0.417 |
|
| 2008 |
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2258-63. PMID 18413640 DOI: 10.1200/Jco.2007.13.6929 |
0.433 |
|
| 2008 |
Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast MA, Fu K, Weisenburger DD, Greiner TC, ... ... Miller TP, et al. Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma Blood. 112: 475-475. DOI: 10.1182/BLOOD.V112.11.475.475 |
0.353 |
|
| 2008 |
Miller TP, Unger JM, Spier C, Stea B, Press OW, Friedberg JW, LeBlanc M, Fisher RI. Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313) Blood. 112: 3598-3598. DOI: 10.1182/Blood.V112.11.3598.3598 |
0.469 |
|
| 2008 |
Friedberg JW, Younes A, Fisher DC, Gordon LI, Moore JO, Czuczman MS, Miller TP, Stiff PJ, Cheson BD, Forero-Torres A, McKinney B, Leonard JP. Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial. Blood. 112: 1004-1004. DOI: 10.1182/Blood.V112.11.1004.1004 |
0.456 |
|
| 2007 |
Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Laboratory Investigation; a Journal of Technical Methods and Pathology. 87: 979-97. PMID 17700562 DOI: 10.1038/Labinvest.3700665 |
0.368 |
|
| 2007 |
Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: 1216-23. PMID 17470451 DOI: 10.1093/Annonc/Mdm114 |
0.353 |
|
| 2007 |
Rimsza LM, LeBlanc ML, Roberts RA, Unger JM, Miller TP, Sabalos CM, Martel RR, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues. Blood. 110: 50-50. DOI: 10.1182/Blood.V110.11.50.50 |
0.343 |
|
| 2007 |
Mahadevan D, Klinkhammer T, Cooke L, Riley C, Choi J, Sinari S, Miller TP, Spier C. CLL Transcript and Serum Profiling Identifies Distinct Oncogenic Pathways in Rai Stage Progression. Blood. 110: 4688-4688. DOI: 10.1182/Blood.V110.11.4688.4688 |
0.352 |
|
| 2007 |
Epner EM, Unger J, Miller T, Rimzsa L, Spier C, Leblanc M, Fisher R. A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma. Blood. 110: 387-387. DOI: 10.1182/BLOOD.V110.11.387.387 |
0.315 |
|
| 2006 |
Miller TP, Spier CM, Rimsza L. Diffuse aggressive histologies of non-hodgkin lymphoma: treatment and biology of limited disease. Seminars in Hematology. 43: 207-12. PMID 17027654 DOI: 10.1053/J.Seminhematol.2006.07.001 |
0.418 |
|
| 2006 |
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4143-9. PMID 16896003 DOI: 10.1200/JCO.2006.05.8198 |
0.313 |
|
| 2006 |
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, ... ... Miller TP, et al. Molecular diagnosis of Burkitt's lymphoma. The New England Journal of Medicine. 354: 2431-42. PMID 16760443 DOI: 10.1056/Nejmoa055759 |
0.388 |
|
| 2006 |
Roberts RA, Wright G, Rosenwald AR, Jaramillo MA, Grogan TM, Miller TP, Frutiger Y, Chan WC, Gascoyne RD, Ott G, Muller-Hermelink HK, Staudt LM, Rimsza LM. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 108: 311-8. PMID 16543468 DOI: 10.1182/Blood-2005-11-4742 |
0.366 |
|
| 2006 |
Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, Unger JM, Leblanc M, Staudt LM, ... ... Miller TP, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood. 107: 1101-7. PMID 16239429 DOI: 10.1182/Blood-2005-04-1510 |
0.338 |
|
| 2006 |
Roberts RA, Rimsza LM, Staudt L, Rosenwald A, Chan W, Dave S, Gascoyne RD, Connors JM, Smeland EB, Muller-Hermelink H, Campo E, Jaffe ES, Wilson W, Tan BK, Fisher RI, ... ... Miller TP, et al. Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL). Blood. 108: 809-809. DOI: 10.1182/Blood.V108.11.809.809 |
0.321 |
|
| 2006 |
Andritsos L, Suhre W, Nahirny M, Chase E, Carroll M, Christian J, Miller TP, Yeager AM. Treatment of Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL) or Hodgkin’s Disease (HD) with High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (HSCT) Using a Novel Mitoxantrone-Containing Preparative Regimen. Blood. 108: 5264-5264. DOI: 10.1182/Blood.V108.11.5264.5264 |
0.413 |
|
| 2006 |
Glinsmann-Gibson BJ, Cycon KA, Murphy SP, Miller TP, Grogan TM, Tome ME, Briehl MM, Rimsza LM. Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line. Blood. 108: 2040-2040. DOI: 10.1182/Blood.V108.11.2040.2040 |
0.399 |
|
| 2006 |
Roberts RA, Miller TP, Rimsza LM. Loss of Major Histocompatibility Class II (MHCII) Gene Expression in Diffuse Large B Cell Lymphoma (DLBCL) Is Not Generally Due to Genetic Mutations in the Coding Regions of CIITA or RFX. Blood. 108: 2039-2039. DOI: 10.1182/Blood.V108.11.2039.2039 |
0.319 |
|
| 2005 |
Mahadevan D, Spier C, Della Croce K, Miller S, George B, Riley C, Warner S, Grogan TM, Miller TP. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Molecular Cancer Therapeutics. 4: 1867-79. PMID 16373702 DOI: 10.1158/1535-7163.Mct-05-0146 |
0.389 |
|
| 2005 |
Tome ME, Johnson DB, Rimsza LM, Roberts RA, Grogan TM, Miller TP, Oberley LW, Briehl MM. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood. 106: 3594-601. PMID 16081686 DOI: 10.1182/Blood-2005-02-0487 |
0.441 |
|
| 2005 |
Press OW, Unger J, Maloney D, Braziel RM, LeBlanc M, Grogan T, Miller TP, Fisher RI. An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911. Blood. 106: 352-352. DOI: 10.1182/Blood.V106.11.352.352 |
0.465 |
|
| 2005 |
Friedberg JW, Leonard JP, Younes A, Fisher DC, Gordon LI, Moore JO, Czuczman MS, Miller TP, Stiff PJ, Cheson BD, Forero-Torres A, Finucane DM, Leigh BR, Molina A. Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL. Blood. 106: 2435-2435. DOI: 10.1182/Blood.V106.11.2435.2435 |
0.348 |
|
| 2004 |
Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology. American Society of Hematology. Education Program. 221-36. PMID 15561685 DOI: 10.1182/asheducation-2004.1.221 |
0.429 |
|
| 2004 |
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. The New England Journal of Medicine. 351: 2159-69. PMID 15548776 DOI: 10.1056/Nejmoa041869 |
0.395 |
|
| 2004 |
Miller TP. The limits of limited stage lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2982-4. PMID 15210737 DOI: 10.1200/Jco.2004.05.926 |
0.463 |
|
| 2004 |
Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 103: 4251-8. PMID 14976040 DOI: 10.1182/Blood-2003-07-2365 |
0.414 |
|
| 2004 |
Hehn ST, Miller TP. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP? Current Hematology Reports. 3: 17-26. PMID 14695845 |
0.351 |
|
| 2004 |
Maloney DG, Pender-Smith B, Unger JM, Braziel RM, Radich J, Press OW, Miller TP, Grogan TM, LeBlanc M, Fisher RI. Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800). Blood. 104: 589-589. DOI: 10.1182/Blood.V104.11.589.589 |
0.33 |
|
| 2004 |
Fisher RI, LeBlanc M, Press OW, Maloney DG, Miller TP. New Treatment Options Have Changed the Natural History of Follicular Lymphoma. Blood. 104: 583-583. DOI: 10.1182/Blood.V104.11.583.583 |
0.407 |
|
| 2004 |
Spier CM, LeBlanc M, Chase EM, Fisher RI, Miller TP. Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736. Blood. 104: 3263-3263. DOI: 10.1182/Blood.V104.11.3263.3263 |
0.467 |
|
| 2004 |
Mahadevan D, Spier C, Croce KD, Miller S, George B, Riley CJ, Warner S, Grogan TM, Miller TP. Gene Expression Profiling of Peripheral T-Cell Lymphoma (PTCL, NOS) and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 104: 2277-2277. DOI: 10.1182/Blood.V104.11.2277.2277 |
0.396 |
|
| 2004 |
Miller TP, Unger JM, Spier C, Stea B, Cantu E, LeBlanc M, Fisher RI. Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014). Blood. 104: 158-158. DOI: 10.1182/Blood.V104.11.158.158 |
0.491 |
|
| 2003 |
Hehn ST, Dorr RT, Miller TP. Mood alterations in patients treated with chlorambucil. Clinical Lymphoma. 4: 179-82. PMID 14715101 DOI: 10.3816/Clm.2003.N.028 |
0.313 |
|
| 2003 |
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, ... ... Miller TP, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. The Journal of Experimental Medicine. 198: 851-62. PMID 12975453 DOI: 10.1084/Jem.20031074 |
0.45 |
|
| 2003 |
Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2466-73. PMID 12829664 DOI: 10.1200/Jco.2003.06.137 |
0.342 |
|
| 2003 |
Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS, Chapman RA, Fisher RI. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1996-2003. PMID 12743154 DOI: 10.1200/JCO.2003.09.047 |
0.31 |
|
| 2003 |
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. 102: 1606-12. PMID 12738671 DOI: 10.1182/Blood-2003-01-0287 |
0.465 |
|
| 2003 |
Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, ... ... Miller TP, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 3: 185-97. PMID 12620412 DOI: 10.1016/S1535-6108(03)00028-X |
0.398 |
|
| 2003 |
de Vos S, Hofmann WK, Grogan TM, Krug U, Schrage M, Miller TP, Braun JG, Wachsman W, Koeffler HP, Said JW. Gene expression profile of serial samples of transformed B-cell lymphomas. Laboratory Investigation; a Journal of Technical Methods and Pathology. 83: 271-85. PMID 12594241 DOI: 10.1097/01.Lab.0000053913.85892.E9 |
0.343 |
|
| 2002 |
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, ... ... Miller TP, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England Journal of Medicine. 346: 1937-47. PMID 12075054 DOI: 10.1056/Nejmoa012914 |
0.449 |
|
| 2002 |
Briggs JH, Algan O, Miller TP, Oleson JR. External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin's lymphoma. American Journal of Clinical Oncology. 25: 34-7. PMID 11823692 DOI: 10.1097/00000421-200202000-00006 |
0.414 |
|
| 2001 |
Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease Journal of Clinical Oncology. 19: 4238-4244. PMID 11709567 DOI: 10.1200/Jco.2001.19.22.4238 |
0.427 |
|
| 2001 |
Braziel RM, Arber DA, Slovak ML, Gulley ML, Spier C, Kjeldsberg C, Unger J, Miller TP, Tubbs R, Leith C, Fisher RI, Grogan TM. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features Blood. 97: 3713-3720. PMID 11389007 DOI: 10.1182/Blood.V97.12.3713 |
0.391 |
|
| 2001 |
Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA, Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 750-5. PMID 11157027 DOI: 10.1200/Jco.2001.19.3.750 |
0.46 |
|
| 2000 |
Taylor CW, LeBlanc M, Fisher RI, Moore DF, Roach RW, Elias L, Miller TP. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial. Anti-Cancer Drugs. 11: 695-700. PMID 11129730 DOI: 10.1097/00001813-200010000-00004 |
0.464 |
|
| 2000 |
Briggs JH, Miller TP. Combined Chemotherapy plus Radiotherapy for Treatment of Early- stage Intermediate- and High-grade Non-Hodgkin's Lymphoma Current Oncology Reports. 2: 176-181. PMID 11122841 DOI: 10.1007/S11912-000-0091-Z |
0.429 |
|
| 2000 |
Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 2010-6. PMID 10811664 DOI: 10.1200/JCO.2000.18.10.2010 |
0.34 |
|
| 1999 |
Moore DF, Brown TD, LeBlanc M, Dahlberg S, Miller TP, McClure S, Fisher RI. Phase II trial of menogaril in non-Hodgkin's lymphomas: A southwest oncology group trial Investigational New Drugs. 17: 169-172. PMID 10638487 DOI: 10.1023/A:1006375301205 |
0.404 |
|
| 1998 |
Wirth A, Prince HM, Wolf M, Machida U, Kami M, Hirai H, Mounier N, Gisselbrecht C, Lepage E, Kosmas C, Malamos NA, Antonopoulos MJ, Decaudin D, Miller TP, LeBlanc M, et al. Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma [1] (multiple letters) The New England Journal of Medicine. 339: 1475-1477. PMID 9841317 DOI: 10.1056/Nejm199811123392012 |
0.357 |
|
| 1998 |
Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma The New England Journal of Medicine. 339: 21-26. PMID 9647875 DOI: 10.1056/Nejm199807023390104 |
0.471 |
|
| 1998 |
Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anti-Cancer Drugs. 9: 135-40. PMID 9510499 DOI: 10.1097/00001813-199802000-00004 |
0.421 |
|
| 1997 |
Miller TP, LeBlanc M, Grogan TM, Fisher RI, Graff JC. Follicular lymphomas: Do histologic subtypes predict outcome? Hematology/Oncology Clinics of North America. 11: 893-900. PMID 9336720 DOI: 10.1016/S0889-8588(05)70468-8 |
0.408 |
|
| 1996 |
Miller TP, Chase EM, Dalton WS, Grogan TM. The phenomenon of multidrug resistance in non-Hodgkin's lymphoma. Cancer Treatment and Research. 85: 107-17. PMID 9043778 DOI: 10.1007/978-1-4615-4129-5_8 |
0.38 |
|
| 1995 |
Fisher R, Dahlberg S, Nathwani B, Banks P, Miller T, Grogan T. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study Blood. 85: 1075-1082. DOI: 10.1182/BLOOD.V85.4.1075.BLOODJOURNAL8541075 |
0.392 |
|
| 1994 |
Fabian CJ, Mansfield CM, Dahlberg S, Jones SE, Miller TP, Van Slyck E, Grozea PN, Morrison FS, Coltman CA, Fisher RI. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Annals of Internal Medicine. 120: 903-12. PMID 8172436 DOI: 10.7326/0003-4819-120-11-199406010-00002 |
0.384 |
|
| 1994 |
Leith CP, Willman CL, Spier CM, Miller TP, Grogan TM. The presence of bcl-1 and bcl-2 gene rearrangements in diffuse small cleaved-cell lymphoma. A disease with diverse molecular and immunophenotypic findings. Diagnostic Molecular Pathology. 3: 178-183. PMID 7981893 DOI: 10.1097/00019606-199409000-00007 |
0.463 |
|
| 1994 |
Atiba JO, Green SJ, Hynes HE, Osborne CK, Miller TP, Davidner M. Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer : a Southwest Oncology Group study Investigational New Drugs. 12: 129-132. PMID 7860229 DOI: 10.1007/Bf00874442 |
0.359 |
|
| 1994 |
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 5: 91-5. PMID 7515652 DOI: 10.1093/Annonc/5.Suppl_2.S91 |
0.493 |
|
| 1994 |
Miller T, Grogan T, Dahlberg S, Spier C, Braziel R, Banks P, Foucar K, Kjeldsberg C, Levy N, Nathwani B. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial Blood. 83: 1460-1466. DOI: 10.1182/Blood.V83.6.1460.Bloodjournal8361460 |
0.462 |
|
| 1994 |
Miller TP, Dahlberg S, Grogan TM, Fisher RI. Southwest Oncology Group clinical trials of chemosensitizers in non-Hodgkinʼs lymphomas: 166 Anti-Cancer Drugs. 5: 73. DOI: 10.1097/00001813-199409001-00166 |
0.327 |
|
| 1993 |
Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, Fisher RI. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy Journal of Clinical Oncology. 11: 644-651. PMID 8478660 DOI: 10.1200/Jco.1993.11.4.644 |
0.476 |
|
| 1993 |
Leigh BR, Fox KA, Mack CF, Baier M, Miller TP, Cassady JR. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure International Journal of Radiation Oncology Biology Physics. 27: 855-862. PMID 8244815 DOI: 10.1016/0360-3016(93)90460-D |
0.46 |
|
| 1993 |
Miller TP, Dahlberg S. Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group. Cancer Treatment and Research. 66: 53-63. PMID 8102863 DOI: 10.1007/978-1-4615-3084-8_4 |
0.444 |
|
| 1993 |
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. The New England Journal of Medicine. 328: 1002-6. PMID 7680764 DOI: 10.1056/Nejm199304083281404 |
0.476 |
|
| 1993 |
Kern WF, Spier CM, Miller TP, Grogan TM. NCAM (CD56)-Positive Malignant Lymphoma Leukemia & Lymphoma. 12: 1-10. PMID 7512851 DOI: 10.3109/10428199309059565 |
0.328 |
|
| 1992 |
Leith CP, Spier CM, Grogan TM, Gonzales G, Rangel CS, Rybski JA, Matzner M, Miller TP. Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets. Journal of Clinical Oncology. 10: 1259-1265. PMID 1634915 DOI: 10.1200/Jco.1992.10.8.1259 |
0.454 |
|
| 1992 |
Kern W, Spier C, Hanneman E, Miller T, Matzner M, Grogan T. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood. 79: 2432-2437. DOI: 10.1182/Blood.V79.9.2432.Bloodjournal7992432 |
0.349 |
|
| 1991 |
Rybski JA, Spier CM, Miller TP, Lippman SM, McGee DL, Grogan TM. Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype. Leukemia & Lymphoma. 6: 31-38. PMID 27457573 DOI: 10.3109/10428199109064876 |
0.376 |
|
| 1991 |
Miller TP, Dahlberg S, Salmon SE, Williamson SK, Belt RJ, Dana BW, Fisher RI. Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study. Journal of Clinical Oncology. 9: 1204-1209. PMID 2045860 DOI: 10.1200/Jco.1991.9.7.1204 |
0.471 |
|
| 1991 |
Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. Journal of the National Cancer Institute. 83: 105-10. PMID 1988684 DOI: 10.1093/Jnci/83.2.105 |
0.329 |
|
| 1991 |
Fisher RI, Longo DL, DeVita VT, Hubbard SM, Miller TP, Young RC. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 2: 33-5. PMID 1710487 DOI: 10.1093/Annonc/2.Suppl_1.33 |
0.413 |
|
| 1991 |
Dalton WS, Grogan TM, Miller TP. The role of P-glycoprotein in drug-resistant hematologic malignancies. Cancer Treatment and Research. 57: 187-208. PMID 1686717 DOI: 10.1007/978-1-4615-3872-1_9 |
0.353 |
|
| 1991 |
Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood. 78: 44-50. PMID 1676918 DOI: 10.1182/Blood.V78.1.44.44 |
0.41 |
|
| 1991 |
Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 17-24. PMID 1670642 DOI: 10.1200/Jco.1991.9.1.17 |
0.378 |
|
| 1991 |
Grogan TM, Miller TP. New biologic markers in non-Hodgkin's lymphomas. Hematology-Oncology Clinics of North America. 5: 925-933. DOI: 10.1016/S0889-8588(18)30393-9 |
0.355 |
|
| 1991 |
Mansfield CM, Fabian C, Dahlberg S, Jones S, Miller TP, Slyck EJb, Grozea P, Morrison F, Coltman CA, Fisher RI. Radiation consolidation following MOP-BAP for stages III & IV Hodgkin's disease, A randomized Southwest Oncology study International Journal of Radiation Oncology Biology Physics. 21: 191. DOI: 10.1016/0360-3016(91)90571-K |
0.316 |
|
| 1990 |
Taylor CW, Crowley J, Williamson SK, Miller TP, Taylor SA, Giri TG, Stephens RL, Livingston RB. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1811-7. PMID 2172473 DOI: 10.1200/Jco.1990.8.11.1811 |
0.438 |
|
| 1990 |
Slymen DJ, Miller TP, Lippman SM, Spier CM, Kerrigan DP, Rybski JA, Rangel CS, Richter LC, Grogan TM. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 986-93. PMID 2140855 DOI: 10.1200/Jco.1990.8.6.986 |
0.425 |
|
| 1990 |
Miller TP, Dahlberg S, Weick JK, Files JC, Eyre HJ, Pendergrass KB, Fisher RI. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1951-8. PMID 1700079 DOI: 10.1200/Jco.1990.8.12.1951 |
0.483 |
|
| 1990 |
Dana BW, Dahlberg S, Miller TP, Hartsock RJ, Balcerzak S, Coltman CA, Carden JO, Hartley K, Fisher RI. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. Journal of Clinical Oncology. 8: 1155-1162. PMID 1694233 DOI: 10.1200/Jco.1990.8.7.1155 |
0.42 |
|
| 1989 |
Jones SE, Miller TP, Connors JM. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy Journal of Clinical Oncology. 7: 1186-1191. PMID 2671279 DOI: 10.1200/JCO.1989.7.9.1186 |
0.381 |
|
| 1989 |
Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 415-24. PMID 2564428 DOI: 10.1200/Jco.1989.7.4.415 |
0.402 |
|
| 1989 |
Collins C, Higano CS, Livingston RB, Griffin BR, Keppen MD, Miller TP. Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study. Cancer Chemotherapy and Pharmacology. 24: 128-132. PMID 2543513 DOI: 10.1007/Bf00263134 |
0.433 |
|
| 1988 |
Miller TP, Lippman SM, Spier CM, Slymen DJ, Grogan TM. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. Journal of Clinical Investigation. 82: 370-372. PMID 3392214 DOI: 10.1172/Jci113598 |
0.422 |
|
| 1988 |
Spier CM, Lippman SM, Miller TP, Grogan TM. Lennert's lymphoma. A clinicopathologic study with emphasis on phenotype and its relationship to survival. Cancer. 61: 517-524. PMID 3257404 DOI: 10.1002/1097-0142(19880201)61:3<517::Aid-Cncr2820610317>3.0.Co;2-1 |
0.454 |
|
| 1988 |
Hersh EM, Miller TP. Malignant Lymphomas in Patients with Human Immunodeficiency Virus Infection Recent Results in Cancer Research. 112: 54-62. PMID 3205960 DOI: 10.1007/978-3-642-83470-7_7 |
0.328 |
|
| 1988 |
Hoff DDV, Green S, Alberts DS, Stock-Novack DL, Surwit EA, Miller TP, Stephens RL. Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study. American Journal of Clinical Oncology. 14: 193-194. PMID 2451882 DOI: 10.1097/00000421-198804000-00011 |
0.387 |
|
| 1988 |
Lippman S, Miller T, Spier C, Slymen D, Grogan T. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype Blood. 72: 436-441. DOI: 10.1182/Blood.V72.2.436.Bloodjournal722436 |
0.448 |
|
| 1988 |
Grogan TM, Lippman SM, Spier CM, Slymen DJ, Rybski JA, Rangel CS, Richter LC, Miller TP. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67 Blood. 71: 1157-1160. DOI: 10.1182/Blood.V71.4.1157.Bloodjournal7141157 |
0.471 |
|
| 1987 |
Fox KA, Lippman SM, Cassady JR, Heusinkveld RS, Miller TP. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. Journal of Clinical Oncology. 5: 38-45. PMID 3806158 DOI: 10.1200/Jco.1987.5.1.38 |
0.44 |
|
| 1987 |
Lippman SM, Grogan TM, Carry P, Ogden DA, Miller TP. Post-transplantation T cell lymphoblastic lymphoma. The American Journal of Medicine. 82: 814-816. PMID 3494399 DOI: 10.1016/0002-9343(87)90020-9 |
0.31 |
|
| 1987 |
Buzaid AC, Lippman SM, Miller TP. Salvage therapy of advanced Hodgkin's disease. Critical appraisal of curative potential. The American Journal of Medicine. 83: 523-532. PMID 2444105 DOI: 10.1016/0002-9343(87)90766-2 |
0.414 |
|
| 1986 |
Miller TP, Cowan JD, Neilan BA, Jones SE. A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study. Cancer Chemotherapy and Pharmacology. 16: 67-9. PMID 3940222 DOI: 10.1007/Bf00255289 |
0.465 |
|
| 1986 |
Braich TA, Salmon SE, Robertone A, Alberts DS, Jones SE, Miller TP, Garewal HS. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. Investigational New Drugs. 4: 269-274. PMID 3818231 DOI: 10.1007/Bf00179595 |
0.332 |
|
| 1986 |
Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN, Wilson HE. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience Journal of Clinical Oncology. 4: 295-305. PMID 3512783 DOI: 10.1200/Jco.1986.4.3.295 |
0.394 |
|
| 1986 |
Miller TP, Chen TT, Coltman CA, O'Bryan RM, Vance RB, Weiss GB, Fletcher WS, Stephens RL, Livingston RB. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study. Journal of Clinical Oncology. 4: 502-508. PMID 3007683 DOI: 10.1200/Jco.1986.4.4.502 |
0.457 |
|
| 1985 |
Ahmann FR, Jones SE, Moon TE, Hammond N, Miller TP, Durie BGM. Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC). Cancer. 56: 730-737. PMID 4016669 DOI: 10.1002/1097-0142(19850815)56:4<730::Aid-Cncr2820560405>3.0.Co;2-E |
0.438 |
|
| 1985 |
Grogan TM, Fielder K, Rangel C, Jolley CJ, Wirt DP, Hicks MJ, Miller TP, Brooks R, Greenberg B, Jones S. Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes. American Journal of Clinical Pathology. 83: 279-288. PMID 2983525 DOI: 10.1093/Ajcp/83.3.279 |
0.332 |
|
| 1984 |
Miller TP, Jones SE, Alberts DS, Mackel C. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas. Investigational New Drugs. 2: 75-77. PMID 6469502 DOI: 10.1007/Bf00173790 |
0.449 |
|
| 1984 |
Schwarte JE, Grogan TM, Hicks MJ, Weinrach RS, Miller TP. Pseudonodular T cell lymphoblastic lymphoma. The American Journal of Medicine. 77: 947-949. PMID 6333817 DOI: 10.1016/0002-9343(84)90548-5 |
0.39 |
|
| 1983 |
Garewal HS, Brooks RJ, Jones SE, Miller TP. Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1: 772-5. PMID 6422004 DOI: 10.1200/Jco.1983.1.12.772 |
0.336 |
|
| 1983 |
Goodman GE, Miller TP, Manning MM, Davis SL, McMahon LJ. Treatment of small cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin), cyclophosphamide (EVAC), and high-dose chest radiotherapy. Journal of Clinical Oncology. 1: 483-488. PMID 6321685 DOI: 10.1200/Jco.1983.1.8.483 |
0.432 |
|
| 1983 |
Miller TP, Jones SE. Initial chemotherapy for clinically localized lymphomas of unfavorable histology Blood. 62: 413-418. DOI: 10.1182/Blood.V62.2.413.413 |
0.466 |
|
| 1980 |
Miller TP, Jones SE. Is there a role for radiotherapy in localized diffuse lymphomas? Cancer Chemotherapy and Pharmacology. 4: 67-70. PMID 6993038 DOI: 10.1007/Bf00254024 |
0.302 |
|
| 1980 |
McMahon LJ, Thomson SP, Nugent CA, Denny WF, Miller TP. Persistent lymphocytopenia as a diagnostic feature of bronchogenic carcinoma. Chest. 78: 583-586. PMID 6251996 DOI: 10.1378/Chest.78.4.583 |
0.306 |
|
| 1979 |
Miller TP, Jones S. Chemotherapy Of Localised Histiocytic Lymphoma The Lancet. 313: 358-360. PMID 85006 DOI: 10.1016/S0140-6736(79)92894-0 |
0.477 |
|
| Show low-probability matches. |